Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2022-10-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 425.2KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 26 October 2022, titled 'Quarterly Activities Report & Appendix 4C'. It provides a detailed quarterly update on clinical trial progress, research activities, and cash flow for the quarter ended 30 September 2022. The inclusion of the Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report. The document contains substantive financial data including cash flow statements, payments, and cash balances, as well as operational updates. It is not merely an announcement of a report but the report itself. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2022-10-25 English
Notice of Annual General Meeting 24 pages 1.5MB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes details about the date, time, and location of the AGM. It contains explanatory notes, proxy forms, voting instructions, and resolutions to be considered at the meeting, such as adoption of the remuneration report, approval of an employee share option plan, and approval of a 10% placement facility. The document also references the 2022 Annual Financial Report but does not contain the report itself. Instead, it is a notice to shareholders about the AGM and the business to be conducted there. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document length is substantial (15,000 characters), consistent with a detailed AGM notice including proxy forms and explanatory notes. Therefore, the correct classification is AGM Information (AGM-R).
2022-10-18 English
Annual Report 62 pages 5.8MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2022' and contains detailed sections typical of an annual report, including an Operations Report, Intellectual Property Report, Directors' Report, Auditor Independence Declaration, Corporate Governance, Consolidated Financial Statements, Notes to Financial Statements, Directors' Declaration, and Independent Auditor's Report. The content includes comprehensive information about the company's activities, clinical development programs, regulatory plans, trial results, and financial statements. The length of the document (15,000 characters) and the detailed financial and operational data confirm it is a full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2022-10-18 English
Corporate Governance Statement 8 pages 180.9KB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement 30 June 2022' and is prepared in accordance with ASX Listing Rule 4.10.3. It covers governance principles, board structure, committees, ethics, and corporate reporting integrity. It references the Annual Report and Directors' Report but does not contain financial statements or detailed financial performance data itself. The content focuses on governance practices, board responsibilities, and compliance with governance principles rather than financial results or audit opinions. The document length is substantial (15,000 characters), indicating it is a full governance statement rather than a brief announcement. Therefore, it fits the category of Governance Information (CGR) rather than Annual Report (10-K), Audit Report (AR), or other categories.
2022-10-18 English
Appendix 4G 12 pages 283.3KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a form used by ASX-listed entities to confirm compliance with corporate governance disclosure requirements. The document includes a checklist of governance principles and recommendations, indicating whether the company has followed them and where disclosures can be found, often pointing to the corporate governance statement or annual report. The document explicitly states it is not a substitute for the corporate governance statement but a verification tool lodged alongside the annual report. It does not contain financial statements or detailed management discussion but is a regulatory compliance filing related to governance disclosures. Given the nature and content, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-10-18 English
Receipt of further R&D Tax Incentive Payment 1 page
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 14 October 2022 regarding the receipt of a further R&D Tax Incentive payment by Antisense Therapeutics Limited. It provides details about the tax refund amounts and the related financial years but does not contain any financial statements, comprehensive financial data, or detailed analysis. The document is short (2571 characters) and serves as an update or notification rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a tax incentive payment without detailed financial disclosures or report content.
2022-10-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.